Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Autolus Therapeutics plc filings document a foreign-issuer ADS structure and material events for a commercial-stage T cell therapy company. The company’s American Depositary Shares trade on the Nasdaq Global Select Market, with each ADS representing one ordinary share, while the ordinary shares are registered in connection with the ADS listing.
Recent Form 8-K disclosures cover financial results, corporate presentations, AUCATZYL revenue updates, pipeline and manufacturing matters, and a master service agreement for lentiviral vector supply used in CAR-T products. The filings also record operational efficiency costs, changes in the company’s independent registered public accounting firm, internal-control disclosures, executive and compensation matters, governance actions and Regulation FD materials.
Autolus Therapeutics plc director Robert Azelby filed an initial ownership report showing three option awards over American Depositary Shares. Each option covers 80,000 underlying shares with exercise prices of $6.84, $3.48 and $2.32, expiring in 2034 and 2035.
According to the footnotes, one grant vested or vests in 36 equal monthly installments commencing on January 9, 2024, another is fully vested and exercisable, and a third vested or vests in twelve equal monthly installments commencing on July 26, 2025. All holdings are reported as direct ownership.
Autolus Therapeutics plc director Rao Madduri Ravin filed an initial Form 3 reporting existing stock option holdings linked to American Depositary Shares. He holds three direct option positions, each covering 80,000 ADS, with exercise prices of $5.68, $3.48, and $2.32 per share and expirations in 2034 and 2035. One option is fully vested and exercisable, while the others vest in equal monthly installments starting on May 1, 2024 and July 26, 2025, indicating a staged compensation structure rather than recent market trades.
Autolus Therapeutics plc director Michael W. Bonney has filed an initial Form 3 showing his beneficial ownership of stock options over American Depositary Shares. The filing lists three option positions: one over 120,000 ADSs with a $5.6800 exercise price expiring on April 1, 2034, and two over 80,000 ADSs each with exercise prices of $3.4800 and $2.3200, expiring on June 28, 2034 and June 26, 2035 respectively. Footnotes explain that one grant vests in 36 equal monthly installments from May 1, 2024, one is already fully vested and exercisable, and another vests in twelve equal monthly installments from July 26, 2025. This Form 3 is a disclosure of existing derivative holdings rather than a report of new market purchases or sales.
Autolus Therapeutics plc executive Patrick Paul McIlvenny, SVP Finance, reports his initial equity holdings. He holds share options over 150,000 American Depositary Shares with a $1.49 exercise price expiring on October 8, 2035, vesting 25% on October 8, 2026 and monthly thereafter. He also holds options over 148,000 ADS at $1.62 expiring on March 4, 2036, vesting 25% on March 4, 2027 and then in 36 monthly installments. In addition, he has 33,000 restricted share units that vest in four equal annual installments starting on March 4, 2027, each RSU representing one ADS.
Autolus Therapeutics plc Chief Financial Officer Robert Dolski filed an initial ownership report showing existing equity awards, rather than new market transactions. The filing lists several share option grants over American Depositary Shares with exercise prices between $1.46 and $2.50, expiring from 2033 to 2036, plus 83,300 restricted share units that vest annually starting on January 26, 2027.
Autolus Therapeutics plc director Linda Bain filed an initial ownership report showing multiple option awards over American Depositary Shares. The holdings include options over 105,000 ADSs at an exercise price of 2.3800, 80,000 ADSs at 3.4800, and additional grants with exercise prices up to 30.2400. Footnotes indicate one option is fully vested and exercisable, while another vests in twelve equal monthly installments commencing on July 26, 2025.
Autolus Therapeutics plc director Robert Iannone filed an initial ownership report detailing his stock option holdings. The filing lists a fully vested option over 105,000 American Depositary Shares with a $2.38 exercise price expiring on June 30, 2033. It also shows an option over 80,000 ADSs at $3.48, expiring on June 28, 2034, which vests in twelve equal monthly installments commencing on July 26, 2025. A further option over 80,000 ADSs with a $2.32 exercise price expiring on June 26, 2035 is reported. These entries describe existing equity incentives and do not reflect any new market purchases or sales.
Autolus Therapeutics plc director John E. Berriman filed an initial ownership report showing his current equity position. He directly holds 136,331 Ordinary Shares, which may be represented by American Depositary Shares, each currently equal to one ordinary share.
He also holds several share options over American Depositary Shares, with exercise prices ranging from $2.32 to $30.24 per share and expirations between February 2028 and June 2035. Footnotes state that certain options are fully vested and exercisable and that one grant vests in twelve equal monthly installments commencing on July 26, 2025.
Autolus Therapeutics plc director and Chief Executive Officer Christian Itin filed an initial Form 3 reporting his equity holdings. He directly owns 1,116,009 Ordinary Shares and 50,000 American Depositary Shares, each currently representing one Ordinary Share.
He also holds multiple share options over American Depositary Shares with exercise prices between 1.46 and 30.29 per share and expirations from 2028 through 2036, plus 350,000 restricted share units that vest in four equal annual installments commencing on January 26, 2027.
Autolus Therapeutics plc director Martin Anton Pule filed an initial insider ownership report listing his existing equity interests in the company. The filing shows multiple share option awards over American Depositary Shares with exercise prices from $0.001 to $30.29 and expiration dates extending through 2036.
He also reports 50,000 restricted share units that vest in four equal annual installments starting on January 26, 2027, with each unit convertible into one American Depositary Share. In addition, he holds 70,000 American Depositary Shares directly. The filing records holdings only and does not reflect new market purchases or sales.